CD26 Expression in B Chronic Lymphocytic Leukaemia
Author Information
Author(s): Bauvois B, Meester I De, Dumont J, Rouillard D, Zhao H X, Bosmans E
Primary Institution: Institut Curie, Paris, France
Hypothesis
The study investigates the expression of CD26 on lymphocytes from patients with B chronic lymphocytic leukaemia compared to healthy subjects.
Conclusion
The study found that CD26 is abnormally expressed on B-CLL cells, suggesting it could be a novel marker for the disease.
Supporting Evidence
- CD26 was undetectable on resting B-cells from normal donors.
- CD26 was expressed on B-cells activated in vitro.
- Induced levels of CD26 were found in 22 out of 25 B-CLL patients.
- Higher transcript levels of the CD26 gene were observed in activated B-cells and B-CLL cells.
Takeaway
Doctors looked at a special protein called CD26 on blood cells from leukemia patients and found it was different from healthy people, which might help in diagnosing the disease.
Methodology
The study used two-colour immunofluorescence analysis and reverse transcription polymerase chain reaction to assess CD26 expression.
Limitations
Further investigation is needed to define the relationship between CD26 expression and other B malignancies.
Participant Demographics
Patients with B chronic lymphocytic leukaemia and healthy subjects.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website